IASLC World Conference on Lung Cancer

IASLC World Conference on Lung Cancer

September 27, 2018
2 min read
Save

LOXO-292 safe, effective for RET-altered non-small cell lung cancer

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Geoffrey Oxnard
Geoffrey R. Oxnard

LOXO-292 appeared well tolerated and demonstrated antitumor activity among patients with heavily pretreated RET fusion-positive non-small cell lung cancer, according to updated interim results of a global, phase 1/phase 2 trial presented at International Association for the Study of Lung Cancer’s World Conference on Lung Cancer.

Researchers reported initial clinical data from the LIBRETTO-001 dose escalation/expansion study of LOXO-292 (Loxo Oncology) — an oral and selective agent in clinical development for cancers that harbor abnormalities in the rearranged during transfection (RET) kinase — at ASCO Annual Meeting in June.

The latest data on 38 patients with RET fusion-positive NSCLC include 3.5 months of additional follow-up, as well as the first follow-up scans of the eight patients most recently enrolled.

Patients had a median of three prior systemic treatment regimens, and 39% had received prior platinum-based chemotherapy and anti-PD-1/PD-L1 therapy.

With a median follow-up of 9.5 months, 96% of responding patients remained on therapy and 92% of patients remained in response.

Researchers observed an overall response rate of 68% (95% CI, 51-83).

“It has been just a few months since ASCO, but the additional follow-up afforded by [these] data provide encouraging evidence that LOXO-292 can deliver durable responses in heavily pretreated patients,” Geoffrey R. Oxnard, MD, associate professor of medicine at Harvard Medical School and thoracic oncologist at Dana-Farber Cancer Institute, said in a company-issued press release. “It was additionally reassuring to see that LOXO-292 appears to be well tolerated at the phase 2 dose of 160 mg [twice daily]. With breakthrough therapy designation in hand, LOXO-292 is moving rapidly through clinical development, so it is important for investigators and patients to pay attention to this emerging target and class of medicines.”

The LIBRETTO-001 trial included a total of 82 patients with advanced solid tumors. Among those evaluable for safety, researchers observed mostly grade 1 adverse events that they deemed not related to treatment.

The most common grade 3 adverse events included diarrhea and headache (both 1%). The most common grade 1 or grade 2 events included diarrhea (grade 1, 15%; grade 2, 7%) fatigue (9%; 13%), dry mouth (21%; 0%), constipation (17%; 2%), hypomagnesemia (12%; 1%), cough (11%; 1%), headache (10%; 1%) and nausea (9%; 4%).

Researchers observed four patients with treatment-related grade 3 tumor lysis syndrome, increased alanine transaminase/aspartate transaminase, diarrhea and thrombocytopenia, which resolved with dose interruption. – by Cassie Homer

Reference:

Oxnard, GR, et al. Abstract OA12.07. Presented at: International Association for the Study of Lung Cancer’s World Conference on Lung Cancer; Sept. 23-26, 2018; Toronto, Canada.

Disclosure: Oxnard reports speaker, advisory or other roles with AstraZeneca, DropWorks, GRAIL, Inivata and Takeda/Ariad; honoraria from Guardant and Sysmex; being a co-author on a patent held by Dana-Farber Cancer Institute for a plasma genotyping approach. Please see the abstract for all other authors’ relevant financial disclosures.